COMMUNIQUÉS West-GlobeNewswire

TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology
11/12/2017
MENLO PARK, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- TeneoBio, Inc. yesterday presented preclinical data on its lead therapeutic candidate, TNB-383B, a multivalent anti-BCMAxCD3 at the American Society of Hematology [...]
Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting
11/12/2017
SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced [...]
Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development
11/12/2017
PLYMOUTH MEETING, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) has promoted Dr. Laurent Humeau to Senior Vice President, Research & Development, reporting to Dr. J. Joseph Kim, [...]
HempAmericana Commences Distributor Agreement Negotiations with Major CBD Oil Distributors
11/12/2017
NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) -- HempAmericana, Inc. (OTC:HMPQ) (the “Company”) is excited to announce it has begun negotiations with high-volume CBD Oil distributors around the country. The company is [...]
Yield10 Bioscience Grants Research License to Monsanto to Evaluate Two Novel Yield Traits in Soybean
11/12/2017
WOBURN, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ: YTEN ) announced today that it has granted a non-exclusive research license to Monsanto Company to evaluate its novel C3003 and C3004 [...]
Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference
11/12/2017
Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN FRANCISCO, Calif., Dec. 11, [...]
Samumed Doses First Patient in Phase 1 Trial of SM08502 for Treatment of Advanced Solid Tumors
11/12/2017
SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Samumed, LLC, today announced the dosing of the first cancer patient in its Phase 1 trial of SM08502, a small molecule Wnt pathway inhibitor in oral tablet formulation. This [...]
Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis
11/12/2017
Eight of 12 patients (67 percent) with cardiac involvement responded to therapy with a median time to cardiac response of 21 days 14 of 24 (63 percent) of patients demonstrated organ response CAEL-101 dosed once weekly [...]
Vital Therapies Added to NASDAQ Biotechnology Index
11/12/2017
SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL ), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced [...]
Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and Exposition
11/12/2017
PHILADELPHIA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that it has [...]
Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting
11/12/2017
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM ), a clinical-stage company developing novel epigenetic therapies, announced today new preclinical data from its novel G9a program for [...]
Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland
11/12/2017
ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the first [...]
Mucodel Pharma LLC Announces Successful Completion of Clinical Study of its Co-Gel Intranasal Naloxone Formulation
11/12/2017
Greensboro, NC, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Mucodel Pharma LLC (“Mucodel”) today announced the successful completion of a pilot clinical study involving intranasal naloxone, a Mucodel product under development for [...]
SIGA Technologies Announces FDA Submission of its New Drug Application for oral TPOXX (tecovirimat) to Treat Smallpox
11/12/2017
– Company requests Priority Review of TPOXX NDA – – If approved, would be the first treatment for deadly smallpox – NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a health [...]
Cancer Genetics advances understanding of immune response and measurement in lymphomas by combining PD-L1 expression analysis with RNA analysis
11/12/2017
Study Presented at the 59 th American Society of Hematology (ASH) Annual Meeting Study focused on DLBCL (Diffuse Large B-Cell Lymphomas) RUTHERFORD, N.J., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq [...]
Reata Pharmaceuticals, Inc. Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma
11/12/2017
IRVING, Texas, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA ) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced the presentation of interim data from [...]
Insider tradings
11/12/2017
Please see enclosed pdf.
Proposal of candidates to the Board of Directors
11/12/2017
The election of board members will be held at the Annual Shareholders’ Meeting on March 13, 2018, and the Board of Directors is today proposing candidates for that one-year term election. The Board of Directors is [...]
REGISTRATION OF CAPITAL INCREASE OF DKK 92,076 AA SHARES AND DKK 920,760 B SHARES BY THE ISSUE OF NEW SHARES COMPLETED
11/12/2017
Copenhagen, 2017-12-11 10:51 CET (GLOBE NEWSWIRE) -- This release does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, [...]

Pages